Critical raw materials supplier, Biosynth, has acquired UK-based Cambridge Research Biochemicals (CRB).
Dilok – stock.adobe.com
Biosynth—supplier of critical raw materials to the life sciences industry—has acquired Cambridge Research Biochemicals (CRB)—an independent producer of custom-made peptide and antibody tools. The acquisition was announced in a May 9, 2023 press release.
Through this acquisition, Biosynth will gain CRB’s expertise in complex peptide chemistry and fluorescent dye labeling, bolstering its peptide division, which has existing operations in the United States and the Netherlands. Additionally, CRB’s custom antibody capacity in Europe will provide further support to Biosynth’s customers through the generation of novel, complex, or unusual mono- and polyclonal antibodies that are not available in catalogs.
“CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division,” said Urs Spitz, CEO and president of Biosynth, in the press release. “Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high-quality antibodies.”
“We are excited to be joining the Biosynth family,” added Emily Humphrys, managing director of CRB, in the press release. “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.”
Source: Biosynth
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.